Literature DB >> 26731300

Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.

Christopher Weidner1, Morten Rousseau1, Robert J Micikas2, Cornelius Fischer1, Annabell Plauth1, Sylvia J Wowro1, Karsten Siems3, Gregor Hetterling3, Magdalena Kliem1, Frank C Schroeder2, Sascha Sauer1,4.   

Abstract

A known (1) and a structurally related new natural product (2), both belonging to the amorfrutin benzoic acid class, were isolated from the roots of Glycyrrhiza foetida. Compound 1 (amorfrutin B) is an efficient agonist of the nuclear peroxisome proliferator activated receptor (PPAR) gamma and of other PPAR subtypes. Compound 2 (amorfrutin C) showed comparably lower PPAR activation potential. Amorfrutin C exhibited striking antiproliferative effects for human colorectal cancer cells (HT-29 and T84), prostate cancer (PC-3), and breast cancer (MCF7) cells (IC50 values ranging from 8 to 16 μM in these cancer cell lines). Notably, amorfrutin C (2) showed less potent antiproliferative effects in primary colon cells. For HT-29 cells, compound 2 induced G0/G1 cell cycle arrest and modulated protein expression of key cell cycle modulators. Amorfrutin C further induced apoptotic events in HT-29 cells, including caspase activation, DNA fragmentation, PARP cleavage, phosphatidylserine externalization, and formation of reactive oxygen species. Mechanistic studies revealed that 2 disrupts the mitochondrial integrity by depolarization of the mitochondrial membrane (IC50 0.6 μM) and permanent opening of the mitochondrial permeability transition pore, leading to increased mitochondrial oxygen consumption and extracellular acidification. Structure-activity-relationship experiments revealed the carboxylic acid and the hydroxy group residues of 2 as fundamental structural requirements for inducing these apoptotic effects. Synergy analyses demonstrated stimulation of the death receptor signaling pathway. Taken together, amorfrutin C (2) represents a promising lead for the development of anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26731300     DOI: 10.1021/acs.jnatprod.5b00072

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.050


  7 in total

1.  Anti-Proliferative and Cytoprotective Activity of Aryl Carbamate and Aryl Urea Derivatives with Alkyl Groups and Chlorine as Substituents.

Authors:  Maxim Oshchepkov; Leonid Kovalenko; Antonida Kalistratova; Maria Ivanova; Galina Sherstyanykh; Polina Dudina; Alexey Antonov; Anastasia Cherkasova; Mikhail Akimov
Journal:  Molecules       Date:  2022-06-04       Impact factor: 4.927

2.  Syntheses of Amorfrutins and Derivatives via Tandem Diels-Alder and Anionic Cascade Approaches.

Authors:  Brian J Curtis; Robert J Micikas; Russell N Burkhardt; Rubin A Smith; Judy Y Pan; Katrina Jander; Frank C Schroeder
Journal:  J Org Chem       Date:  2021-03-04       Impact factor: 4.198

Review 3.  Multiple Targets of Salicylic Acid and Its Derivatives in Plants and Animals.

Authors:  Daniel F Klessig; Miaoying Tian; Hyong Woo Choi
Journal:  Front Immunol       Date:  2016-05-26       Impact factor: 7.561

Review 4.  Natural Salicylates and Their Roles in Human Health.

Authors:  Fatema Yeasmin; Hyong Woo Choi
Journal:  Int J Mol Sci       Date:  2020-11-28       Impact factor: 5.923

Review 5.  Natural Products Targeting the Mitochondria in Cancers.

Authors:  Yue Yang; Ping-Ya He; Yi Zhang; Ning Li
Journal:  Molecules       Date:  2020-12-28       Impact factor: 4.411

6.  Mertensene, a Halogenated Monoterpene, Induces G2/M Cell Cycle Arrest and Caspase Dependent Apoptosis of Human Colon Adenocarcinoma HT29 Cell Line through the Modulation of ERK-1/-2, AKT and NF-κB Signaling.

Authors:  Safa Tarhouni-Jabberi; Ons Zakraoui; Efstathia Ioannou; Ichrak Riahi-Chebbi; Meriam Haoues; Vassilios Roussis; Riadh Kharrat; Khadija Essafi-Benkhadir
Journal:  Mar Drugs       Date:  2017-07-20       Impact factor: 5.118

7.  Insights into pancreatic β cell energy metabolism using rodent β cell models.

Authors:  Karl J Morten; Michelle Potter; Luned Badder; Pamela Sivathondan; Rebecca Dragovic; Abigale Neumann; James Gavin; Roshan Shrestha; Svetlana Reilly; Kanchan Phadwal; Tiffany A Lodge; Angela Borzychowski; Sharon Cookson; Corey Mitchell; Alireza Morovat; Anna Katharina Simon; Johanna Uusimaa; James Hynes; Joanna Poulton
Journal:  Wellcome Open Res       Date:  2019-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.